Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02215928 · ClinicalTrials.gov registry record
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors
A clinical trial of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Stanford University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT02215928 is a study of Unspecified Adult Solid Tumor, Protocol Specific that is actively recruiting participants, run by Stanford University. The registered enrollment target is 100 participants, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02215928, a study of Unspecified Adult Solid Tumor, Protocol Specific, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies using genomic profiling to recommend anticancer treatment to patients with cancer that has spread beyond the original site of the tumor (metastatic cancer). Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. This information can then be used to recommend treatments that may be more likely to result in a beneficial response. It is not yet known whether genomic profiling will detect abnormalities that can be used to make treatment recommendations and whether treatment based on genomic profiling is more effective than standard treatment.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
- GENETIC mutation analysis
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-07-28 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02215928
The ClinicalTrials.gov registry entry for NCT02215928 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (80% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02215928 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02215928 about?
NCT02215928 is a clinical study titled "Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors". This research trial studies using genomic profiling to recommend anticancer treatment to patients with cancer that has spread beyond the original site of the tumor (metastatic cancer). Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. Th...
What is the current status of trial NCT02215928?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2014-07-28. Estimated completion is 2026-12.
What conditions does trial NCT02215928 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT02215928?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER), mutation analysis (GENETIC).
Who is sponsoring clinical trial NCT02215928?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02215928 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
RECRUITING
-
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
RECRUITING
-
Registry of Older Patients With Cancer
RECRUITING
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RECRUITING
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Assessment Tool for Older Patients With Cancer
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.